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1. Introduction 
Implantable cardioverter-defibrillators (ICDs) reduce mortality by terminating ventricular 
arrhythmias (VAs), and it has become widely accepted that this is done by delivering 
shocks. From the initials of ICD therapy it is known that ICD shocks are associated with 
reduced quality of life. Most importantly, recent accumulated evidence indicates a clear 
association among shocks (appropriate and inappropriate) and increased risks of heart 
failure (HF) and death (Poole et al, 2008). Knowing that, one of our major objectives when 
dealing with an ICD patient has to be reducing shocks while keeping the certainty that all 
the VAs are adequately terminated. 
When trying to reduce shocks our focus should be dual, inappropriate and unnecessary 
therapies. Inappropriate shocks are generally defined as those not delivered for ventricular 
tachycardia (VT) or fibrillation (VF), and may be due to oversensing (double counting of 
right and left ventricular depolarization, T-wave oversensing, noise, etc) or to atrial 
arrhythmias with rapid ventricular conduction. Unnecessary shocks are those that could 
have been avoided using other means of terminating the VT, namely antitachycardia pacing, 
or allowing the VT to spontaneously finish, in case of non-sustained episodes, prolonging 
the number of intervals needed to detect and initiate therapy.  
Depending on the trial, only 3–35% of shocked episodes were sustained VT/VF that 
absolutely require a shock for termination. When considering the number of shocks 
delivered for SVT, T-wave oversensing (TWOS) and lead noise, primary prevention patients 
may experience more inappropriate shocks than shocks for VT/VF. This highlights the need 
for improved shock reduction strategies.  
During this chapter we will review the most recent developments and algorithms to avoid 
inappropriate and unnecessary shocks. 
2. Where do we stand now? 
2.1 The problem of inappropriate and unnecessary shocks 
ICD therapy has clearly shown its benefit in reducing sudden death and is now an accepted 
therapy, with increasing number of patients receiving a device. One of the most serious 
problems with this therapy is the rate of unnecessary and inappropriate shocks, that ranges 
between 10 and 25% on different studies (Figure 1), with the added limitation of many trials 
not reporting this data. 
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Fig. 1. Rate of inappropriate therapy (in orange) in some of the principal ICD trials. 
Multiple studies have reported that ICD shocks are associated with several negative 
outcomes, both in the short term -such as increased troponin levels, decreased cardiac index 
or acutely reduced contractility-, as in the long term-increasing hospitalization rate or 
reducing quality of life. Inappropriate shocks might also be proarrhythmic in up to 10% of 
episodes and also reduce battery life. 
Moreover, recent evidence indicates a clear association among appropriate shocks, 
inappropriate shocks, and increased risks of heart failure and death (Figure 2, reproduced 
from Poole et al, 2008). These data also demonstrates that the higher the number of shocks, 
the higher the death hazard ratio. An important corollary is that, even if it is impossible to 
completely avoid shocks, any reduction we obtain translates into lower hospitalization and 
death risk. 
 
 
Fig. 2. Hazard Ratios for the association of ICD shock with the risk of death, according to 
shock type. Panel A shows the hazard ratios for the association of shock types (appropriate, 
inappropriate or both) with the risk of death. Panel B shows the adjusted hazard ratios for 
the risk of death according to the number of appropriate or inappropriate shocks.  
From the SCD-HeFT we know that death from all causes was increased among patients who 
received an appropriate shock by a factor of nearly 6, with 30% of these deaths occurring 
within 24 hours after the first appropriate shock. After exclusion of these patients (in whom 
an appropriate shock was simply a harbinger of imminent death), appropriate shocks were 
still associated with a risk of death that was increased by a factor of 3. Data from MADIT II 
trial (Daubert et al, 2008) also clearly showed how shocks are associated with increased risk 
of all-cause mortality (by a factor of 3 after an appropriate ICD shock).  
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It is unclear whether this is due to the ventricular arrhythmia itself or to the shocks, but 
evidence is increasingly showing that ICD discharges are harmful per se. Pooled data from 
PainFREE I & II, EMPIRIC and PREPARE (Sweeney et al, 2010) has clearly shown the 
impact on survival depending on the type of therapy delivered by the ICD (Figure 3), 
demonstrating that antitachycardia pacing (ATP) termination of the VA can reduce the risk. 
 
 
Fig. 3. Survival rates by rhythm and therapy type. Survival among patients treated only 
with ATP was identical to that in patients with no VT, whereas survival among patients 
who received shocks was significantly worse (reproduced from Sweeney et al, 2010). 
An important issue to be considered is the high rate of inappropriate therapies in published 
studies, ranging from 10 to 25%. Benign events such as atrial fibrillation, supraventricular 
tachycardia (SVT), extra-cardiac noise, intracardiac oversensing, and nonsustained VT/VF 
are inappropriately treated with shocks by the ICD. Inappropriate therapy delivery remains 
the most frequent complication in patients with ICDs resulting in psychological distress, 
proarrhythmia, and battery life reduction. We could think that delivery of inappropriate 
shocks is something overcome in nowadays trials, but recent data from the MADIT II trial 
(Daubert et al, 2008) shows that one or more inappropriate shocks occurred in 83 (11.5%) of 
the 719 MADIT II ICD patients. Inappropriate shock episodes constituted 184 of the 590 total 
shock episodes (31.2%).  
Atrial fibrillation was the most common trigger for inappropriate shock (44%), followed by 
supraventricular tachycardia (36%), and by abnormal sensing (20%). Due to the fact that the 
majority of inappropriate shocks are delivered because of a supraventricular rhythm 
incorrectly classified by the device (see Figure 4), nowadays most devices on the market 
contain some form of SVT discriminator.  
Other causes of inappropriate therapy include oversensing of diaphragmatic potentials or 
myopotentials, T-wave oversensing, double or triple counting of intracardiac signals, lead 
fractures or header connection problems, lead chatter or noise, and electromagnetic interference.  
Strategies to reduce inappropriate therapy using device programming rely on the ability to 
distinguish supraventricular and atrial arrhythmias from ventricular tachycardia. Avoiding 
therapy for nonsustained ventricular arrhythmias and increasing the role of antitachycardia 
pacing to terminate ventricular tachycardia are key approaches to reducing shocks for 
ventricular arrhythmias. 
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Fig. 4. Main causes of inappropriate shocks in ICD patients. 
2.2 Algorithms to avoid inappropriate shocks 
Although dual-chamber discrimination algorithms are frequently based on measurements of 
AV association, algorithms used in single-chamber ICDs focus on frequency-related 
tachycardia characteristics  (beat-to-beat interval variability -rate stability- and abruptness of 
tachycardia initiation –onset-) and electrogram (EGM) morphology. 
2.2.1 Sudden onset 
Initially developed to avoid misclassification of sinus tachycardia as VT, the algorithm is 
based on the degree of prematurity of the first tachycardia cycle compared to the previous 
ones. If a tachycardia episode is declared, the device measures the RR intervals prior to the 
episode looking for the shortest RR interval. Then it compares this shortest RR interval with 
the RR interval initiating the episode. If the difference is above the programmed, the sudden 
onset criterion is satisfied. If the difference is below the programmed one, a non-sudden 
onset will be declared and therapy will be inhibited until the end of the sustained rate 
duration period if activated. 
2.2.2 Stability 
Measures the variability between RR intervals during tachycardia and was developed to avoid 
inappropriate shocks due to fast atrial fibrillation, a typically unstable rhythm. The device 
measures the stability during the programmed duration of the episode. If duration is satisfied, 
the mean difference in stability between consecutive RR intervals is compared to the 
programmed one. If stability is below the programmed one, the device declares the episode 
stable. If stability is above the programmed one, the device declares the episode unstable and 
therapy will be inhibited. Then it will continue to measure stability as long as the rate criterion 
is satisfied. If tachycardia becomes stable or the sustained rate duration period is satisfied, 
therapy will be initiated if the rate persists above the programmed cut-off rate. 
Sudden onset carries a greater risk of error, since it analyses the rhythm only once upon 
initiation. In contrast, stability constantly reanalyzes the rhythm. These two algorithms have 
been traditionally underused due to concern of misclassification of a true VT as a non-
shockable rhythm by the device, thereby continuously withholding a necessary therapy. 
However, several publications have demonstrated that programming sudden onset and 
stability detection criteria with a sustained rate duration safety net for triggering tachycardia 
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therapy results in appropriate device management in most patients with supraventricular 
and slow ventricular tachycardias (Brugada et al, 1998). 
Recent data from the MADIT II trial (Daubert et al, 2008) showed that the stability detection 
algorithm was programmed less frequently in patients receiving inappropriate shocks (17% 
vs. 36%, p: 0.030), so we still have room to improve ICD programming by using 
consolidated algorithms. 
2.2.3 Morphology algorithms 
Morphology algorithms are the only single-chamber discriminators capable of 
distinguishing VT from abrupt-onset SVTs with regular V-V intervals, such as atrial flutter 
or atrial tachycardia. When integrated into dual-chamber algorithms, morphology 
algorithms may enhance discrimination of tachycardias with 1:1 AV relationships and 
detection of VT during atrial fibrillation (Swerdlow et al, 2002). 
All morphology algorithms share general steps. (1) Create a template electrogram of 
baseline rhythm. (2) Construct a quantitative representation of this template. (3) Record 
electrograms from an unknown tachycardia. (4) Time align template and tachycardia 
electrograms. (5) Construct a quantitative representation of each tachycardia electrogram. 
(6) Compare the representation of each tachycardia electrogram with that of the template to 
determine the degree of morphologic similarity of the corresponding electrograms. (7) 
Classify each tachycardia electrogram as a morphology match or nonmatch with the 
template. (8) Classify the tachycardia as VT or SVT based on the fraction of tachycardia 
electrograms that match the template. The major differences among morphology algorithms 
are the electrogram source(s), methods of filtering and alignment, and waveform features 
used to compare tachycardia and template electrograms. 
 
 
Fig. 5. Morphology analysis of tachycardia EGMs using the wavelet transform (Medtronic) 
The wavelet transform of the baseline rhythm template EGM is constructed and stored. 
When tachycardia is detected, each of the last eight tachycardia EGMs preceding detection is 
aligned with the template EGM. The wavelet transform of each EGM is performed and a 
match-percent score that describes the degree of morphological similarity to the template is 
calculated in real time. If the matching score is higher than the programmable threshold, VT 
is rejected. If the matching score is lower than the threshold, VT is confirmed and 
corresponding therapy initiated. 
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The Rhythm ID feature in Boston Scientific ICDs uses the vector timing and correlation 
algorithm -which incorporates both timing as well as morphological information- for 
supraventricular tachycardia discrimination. Clinical trials demonstrated high sensitivity 
and specificity of this feature in discriminating between ventricular tachycardia and 
supraventricular tachycardia. On detection of the unknown rhythm (when the ventricular 
tachycardia rate detection criteria is met), the vector timing and correlation algorithm 
compares the unknown rhythm beat-by-beat to a stored template of normal sinus rhythm. 
First, the algorithm aligns the signals coming from the near field and the far field EGMs. 
After that, the feature correlation coefficient computed over more than 8 points in the time-
aligned signals is used for the comparison (see Figure 6).  
 
 
Fig. 6. Schematic representation of Rhythm ID algorithm functioning. 
There are several limitations of morphology algorithms, such as: 
• Truncation of EGMS that exceed the programmed range of the algorithm. Truncation 
both removed some electrogram features for analysis, and altered the timing of the 
highest peak used for alignment. It is, therefore, recommended to verify that recorded 
EGMs exceed 3 mV and are not clipped. 
• Miopotential interference. 
• Alignment errors: algorithm aligns electrograms in time based on their highest peaks. If 
an electrogram has two peaks of nearly equal amplitude, minor variation in their 
relative heights may result in an alignment error. 
• Morphology algorithms may be applied in patients with baseline intraventricular 
conduction delays. However, rate-related aberrancy during rapidly conducted atrial 
fibrillation is likely to be misclassified. 
As we stated in a recent publication (Toquero et al, 2009), probably morphology algorithms 
as an SVT discrimination criteria should be considered as an effective tool when used alone 
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but, in order to maximize the benefits, a lower limit of 500 ms and the concomitant use of 
other discrimination criteria or combination with a high rate time-out feature should be 
considered. When programming several discriminators together, the more we use the better 
the specificity for SVT but carries a greater risk of underdetecting VT, so once again we have 
to individualize and tailor the programming to each patient.  
2.2.4 Dual chamber detection 
Dual chamber devices allow for ventricular and atrial rate analysis during tachyarrythmias, 
as well as establishing a relationship between them. As a concept, if the rhythm is faster in 
the ventricular chamber the device will deliver therapy. At the very beginning, it was 
expected a dramatic reduction of inappropriate shocks due to atrial tachyarrhythmias 
compared to single chamber devices, but finally it did not turn out to be that way due to 
atrial undersensing problems or difficulties programming the algorithm. 
Evidence recently published (Ricci et al, 2009) shows that dual-chamber ICDs compared to 
single-chamber ICDs reduced the incidence of an endpoint composed by permanent AF, AF-
related hospitalizations, and ICD shocks deemed inappropriate due to AF misclassification. 
So dual chamber detection helps to improve SVT discrimination but probably this is not 
enough to justify the implantation of a DDD device on this sole aim.  
There are other algorithms intended to adequately discriminate SVT from true VT. Detailed 
description of PARAD+ from Sorin or SMART from Biotronik (using dual chamber 
discrimination) is beyond the aim of this chapter. Briefly, the PARAD+ combines several 
features of the tachyarrhythmia that are analyzed and inputted into a branching algorithm. 
It is the only algorithm that uses the chamber of acceleration to differentiate atrial from 
ventricular arrhythmias. It incorporates a feature termed VT long cycle, which monitors for 
longer intervals when the rhythm is classified as stable. Unlike VT, occasional longer RR 
intervals are common in rapid AF. SMART algorithm, like St Jude Devices, relies on a rate 
branch algorithm for discrimination. If the RR interval is shorter than the PP interval (V>A), 
the rhythm is considered VT.  
For further description of different algorithms of several manufacturers, we strongly 
recommend the recent review by Mansour and Khairy, PACE 2011. 
3. Ways to avoid shocks and new strategies 
Even though it is plausible that shocks somehow have an adverse effect on myocardial 
function, this is unlikely to be a major factor. It is much more likely that the occurrence of a 
ventricular arrhythmia that causes a shock is signalling a meaningful change in the patient’s 
clinical status. The important message is that the first occurrence of shocks is not a random 
event in an otherwise stable clinical course but a sign of clinical deterioration in the 
underlying disease process. Possible causes of shocks are to be considered, including a 
worsening of heart failure and myocardial ischemia. 
There are several complementary ways to avoid both inappropriate and unnecessary 
shocks: 
3.1 Optimize medical therapy, look for isquemia and other triggers, and early ablate 
clinical VTs 
Antiarrhythmic medication is administered in patients with an ICD for a number of reasons. 
Most importantly, drug therapy can reduce or eliminate ICD shocks by suppressing 
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ventricular arrhythmias, or by slowing VT to such a degree that it can be terminated with 
programmed ATP. In addition to the suppression of such “appropriate” shocks, 
antiarrhythmic therapy may suppress the “inappropriate” shocks precipitated by 
supraventricular arrhythmias (primarily atrial fibrillation). In routine practice, adjunctive 
antiarrhythmic therapy is administered to between 49% and 69% of patients who have an 
ICD. 
The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial 
was a randomized clinical trial evaluating the efficacy of amiodarone plus β-blocker and 
sotalol versus β-blocker alone for reduction of ICD shocks (Connelly et al, 2006). In 412 
patients studied, mainly secondary prevention, with a median follow up of 359 days, the 
authors demonstrated that shocks occurred in 41 patients (38.5%) assigned to β-blocker 
alone, 26 (24.3%) assigned to sotalol, and 12 (10.3%) assigned to amiodarone plus β-blocker 
(Figure 7). 
 
 
Fig. 7. Cumulative rate of shocks for the three treatment groups (β-blocker, Sotalol and 
Amiodarone+β-blocker) by time since randomization (Reproduced from Connolly et al, 
OPTIC trial). 
The OPTIC study applies primarily to ICDs placed as secondary prevention, in which 
sustained ventricular arrhythmias have been clinically observed. There are less data to 
support the use of antiarrhythmic agents in patients with prophylactic or primary prevention 
ICD therapy and this group appears to have less frequent need for such therapy; thus, 
empirical antiarrhythmic therapy cannot be recommended for this setting. For patients who 
receive an ICD for secondary prevention, one could argue for empirical initiation of 
amiodarone or sotalol. However, such pharmacological intervention has important trade-offs. 
Adverse lung and thyroid effects were common among patients receiving amiodarone over 
just 1 year, and it can be expected that toxicity would be even more common over longer 
follow-up. In the OPTIC study, these and other adverse effects resulted in the discontinuation 
of 18% of those patients receiving amiodarone and 24% of those patients receiving sotalol. As 
noted by the authors, most patients taking β-blocker alone will not receive an ICD shock and 
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could avoid the inconvenience, cost, and risk of antiarrhythmic therapy. At present, all 
patients with an ICD who tolerate such therapy should receive a β-blocker.  
Amiodarone is known to be effective in the prevention of ventricular arrhythmias; however, 
SCD-HeFT itself finally put to rest the notion that amiodarone could improve survival 
among patients with heart failure. Addition of amiodarone or substitution with sotalol 
cannot be advocated for all patients and should be considered on an individual basis.  
Triggers of VT include electrolyte abnormalities (e.g., hypokalemia, hypocalcaemia, and 
hypomagnesaemia), ischemia, inflammation, and sleep apnea.  It can also be triggered by 
drugs (sympathomimetic agents, digitalis toxicity, drugs prolonging the QT complex, etc.). 
Hypokalemia is the most important arrhythmia trigger clinically, followed by 
hypomagnesaemia. Hyperkalemia may also predispose to VT and VF, particularly in 
patients with structural heart disease. Electrolyte disturbances and ischemia are frequent VT 
triggers in ICD patients with reduced ejection fraction and heart failure. The greater 
prognostic significance of appropriate ICD shocks in patients with ischemic heart failure 
makes revascularization another possible intervention; however, there are currently no 
prospective data to suggest that this will improve prognosis. So, when facing a patient 
receiving a shock, we should be aware of all the possible triggers of VTs, actively look for 
them and make every effort needed to control these triggers.  
The Ventricular Tachycardia Ablation in Coronary Heart Disease (VTACH) study (Kuck et 
al, 2010) assessed the potential benefit of catheter ablation before implantation of a 
cardioverter defibrillator in 110 patients that were randomized to receive catheter ablation 
and an ICD or ICD alone. They showed that time to recurrence of VT or VF was longer in 
the ablation group (median 18 months) than in the control group (5 months). At 2 years, 
estimates for survival free from VT or VF were 47% in the ablation group and 29% in the 
control group. The authors conclude that prophylactic VT ablation before defibrillator 
implantation seemed to prolong time to recurrence of VT in patients with stable VT, 
previous myocardial infarction, and reduced LVEF and should therefore be considered 
before implantation of an ICD in such patients. 
 
 
 
 
 
 
Fig. 8. Data from the VTACH trial. On the left, Kaplan Kaplan-Meier curves for survival free 
from VT or VF. On the right, estimates of survival free from hospital admission for cardiac 
reasons (Reproduced from V-TACH trial). 
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According to the latest guidelines of the American Heart Association, the American College 
of Cardiology, and the European Society of Cardiology, catheter ablation is indicated as 
adjunctive therapy in selected patients who have an ICD and who receive multiple shocks 
as a result of sustained ventricular tachycardia that is not manageable by reprogramming of 
the ICD or drug therapy. 
Some evidence already exists on prophylactic ablation in ICD patients to prevent VTs and 
shocks. The SMASH-VT trial (Reddy et al, 2007) included 128 ischemic patients that were 
ICD implanted for spontaneous ventricular tachycardia or fibrillation. They were randomly 
assigned to defibrillator implantation alone or defibrillator implantation with adjunctive 
catheter ablation. Ablation was performed with the use of a substrate based approach in 
which the myocardial scar is mapped and ablated while the heart remains predominantly in 
sinus rhythm. During a mean follow-up of 22.5±5.5 months, twenty one patients assigned to 
defibrillator implantation alone (33%) and eight patients assigned to defibrillator 
implantation plus ablation (12%) received appropriate ICD therapy. So the authors conclude 
that prophylactic substrate-based catheter ablation reduced the incidence of ICD therapy in 
patients with a history of myocardial infarction who received ICDs for the secondary 
prevention of sudden death. 
3.2 Optimize device programming 
3.2.1 Tailored programming for each patient 
The first way to avoid inappropriate shocks is to program the device considering patient 
characteristics such as age, underlying myocardiopathy, primary or secondary indication 
and concomitant arrhythmias or, at least, risk of future development. For instance, previous 
investigations have demonstrated substantial differences in frequency, rate, and 
mechanisms of tachycardia observed in patients with ICDs implanted for primary versus 
secondary prevention indications. The primary prevention patient population has been 
reported to have a lower incidence of ventricular arrhythmias compared with secondary 
prevention patients. Consequently, a higher proportion of ICD therapies in primary 
prevention patients could be due to inappropriate detections and therapies primarily due to 
arrhythmias such as sinus tachycardia and atrial fibrillation. 
3.2.1.1 Cut-off rates 
ICD recipients with primary compared to secondary prevention indications experience 
faster ventricular tachyarrhythmias, with average rates of 200 versus 153 beats per minute 
(bpm), respectively. In contrast, clinical supraventricular tachycardia (SVT) usually ranges 
between 160 and 180 bpm. Also patients under antiarrhythmic drug therapy experience 
slower tachycardias. For patients with secondary prevention indications, a safety margin of 
30–60 ms between the slowest spontaneous or induced VT and the cut-off rate has been 
recommended (Mansour and Khairy, 2011). 
If the VT rate is unknown or if a primary prevention patient is receiving antiarrhythmic 
therapy, an empirically programmed rate of 150–160 bpm appears reasonable. A higher rate of 
170-175 bpm could be used in youngest patients, typically suffering from channelopathies. 
Modern devices allow us to program different detection zones (Ventricular Fibrillation-VF, 
Fast Ventricular Tachycardia-FVT and Ventricular Tachycardia-VT). Depending on ICD 
indication we can select one, two or the three of them, with different detection criteria and 
therapies on each one. In certain patients could be interesting to program a detection zone with 
no therapy, using the device to monitor the occurrence of slow tachycardias.  
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Limiting the use of SVT discriminators for tachycardias of 188 bpm or slower results in 
inappropriate ICD therapy since 22–44% of SVTs conduct faster than 188 bpm. Since the 
majority of SVTs leading to ICD shock have rates less than 230 bpm some authors (Volosin 
et al, 2011) have proposed the use of SVT discriminators for rates up to 230 bpm. Our usual 
policy is to program it up to 220 bpm.  
3.2.1.2 Timers to override discriminators 
Sustained rate duration (SRD; Boston Scientific, Natick, MA, USA), High rate time out (HRT; 
Medtronic, Minneapolis, MN, USA), SVT time out (St. Jude Medical, St. Paul, MN, USA), 
and sustained VT (Biotronik GmbH, Berlin, Germany) are timers used to override 
discriminators. Once the programmed timer elapses, therapy is delivered even if it had been 
appropriately withheld.  
The literature suggests that this safety feature is of little value, especially for dual chamber 
devices. A reasonable option could be to activate the overriding timer while extending its 
nominal duration (in our opinion to, at least, 3 min). 
3.2.1.3 Detection time/intervals 
Classifying an arrhythmia as sustained is a somewhat arbitrary balance between 
overtreating otherwise self-terminating arrhythmias and delaying therapy for potentially 
unstable arrhythmias. The trend has been toward programming longer detection times, due 
to the fact that nominal detection settings are likely excessively conservative, erring on the 
side of overtreating nonsustained VT. 
Recent publications (Wilkoff et al, 2008) have shown that adequately programming 
detection criteria, increasing the number of RR intervals needed to detect the arrhythmia 
and thus allowing for non-sustained VTs to spontaneously terminate (30 of 40 beats on this 
study), reduce number of shocks without increasing risk of syncope or serious adverse 
events. 
 
 
Fig. 9. Kaplan-Meier curves show the percentage of patients in each study cohort receiving a 
first shock during the first 12 months of follow-up due to: (left) true VT/VF; (middle) true 
SVT/other; on the right, Kaplan-Meier curves show the mortality rate (reproduced from 
Wilkoff et al, PREPARE study). 
3.2.2 Improve correct detection 
3.2.2.1 SVT discriminators 
The main arguments against systematically enabling discriminators are their reliability and 
associated risks of underdetecting VT. With single chamber discriminators, underdetection 
occurs in 0–0.4% of VT episodes with stability, 0–2% with morphology, and 0.5–5% with 
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onset criteria. For dual-chamber devices, VT underdetection has been reported in 0.6–1% of 
events. 
Discriminators appear most useful in patients with secondary prevention ICDs or under 
antiarrhythmic drug therapy, since lower programmed cut-off rates expose them to a higher 
risk of inappropriate therapy for SVT. We currently program discriminators up to a rate of 
220 bpm with a high-rate timer along with discriminators. In Medtronic’s most recent ICD 
model (ProtectaTM), the SVT limit is nominally programmed to 230 bpm within the VT 
zone. For Boston and Sorin devices, discriminators apply to the entire VT zone. 
In the event of inappropriate VT detection, reported values of onset, stability, AV 
association, and/or morphology should be examined, when available, to guide further 
programming to optimize cut-off values. 
3.2.2.2 Algorithms to avoid shocks due to noise or T wave oversensing 
New algorithms capable of increasing specificity without affecting sensitivity for VT 
detection have been developed by different ICD manufactures. Oversensing of T-waves and 
noise due to lead problems (loose set-screw or lead fractures) are among the leading causes 
of noise-driven VF detection. 
One of these new algorithms recently introduced is intended to reduce inappropriate shocks 
caused by fractures of implantable cardioverter-defibrillator leads (Swerdlow et al, 2008). 
This lead-integrity algorithm (LIA), which can be downloaded into presently implanted 
Medtronic implantable cardioverter-defibrillators, alerts the patient and/or physician when 
triggered by either abnormally high impedance or sufficient evidence of nonphysiological, 
rapid oversensing. Once the LIA is triggered, it sets the programmed number of intervals to 
detect (NID) at 30 of 40 intervals to reduce inappropriate shocks, an audible alert sounds 
immediately and every 4 hours thereafter, and transmits a wireless, internet-based alert if 
enabled. The authors demonstrated on 15970 patients with Fidelis leads and 95 other 
fractured leads that increasing the NID reduced inappropriate shocks and the LIA provided 
at least a 3-day warning of inappropriate shocks in 76% of patients. 
A new T-wave discrimination algorithm by Medtronic analyzes the sensing electrogram for 
alternating patterns of amplitude and frequency content by comparing the standard sensing 
signal to a first-order difference signal that attenuates low-frequency content dominating T-
waves. Other functions like SenseAbility available in St Jude Medical ICDs allows avoidance 
of TWOS by means of four key parameters: Threshold start, decay delay, maximum 
sensitivity and refractory periods (see Figure 10 for explanation). The algorithm adjusts the 
sensitivity setting based on intrinsic signals and changes sensitivity on every beat so it 
adjusts as the patient’s intrinsic activity changes. 
The new lead noise oversensing algorithm available in Medtronic devices analyzes the far-
field EGM (e.g., right ventricular (RV) coil-can) in an amplitude measurement window 
centered around each event sensed on the near-field EGM (e.g., RV tip-RV ring). The 
concept behind RV Lead Noise Discrimination algorithm is that lead noise oversensing is 
typically isolated to the near-field EGM (RVtip-RVring sense channel). Therefore, a far-field 
electrogram signal (Can to RV coil or RV coil to superior vena cava –SVC-) is used to 
confirm that VT/VF senses on the near-field electrogram are not present on the far-field 
signal in the case of lead noise (see Figure 11). Oversensing due to a lead or connection 
problem is identified when the peak to peak amplitudes seen on the far field signal have a 
large disparity, indicating that these amplitude measurement windows are sensing both R-
wave as well as absence of R-waves (isoelectric potentials). 
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Fig. 10. SenseAbility algorithm: Threshold Start is a programmable percentage of the 
previous peak amplitude. Decay Delay “delays” the time before the linear decay occurs (60 
ms on this example). Max Sensitivity defines the most sensitive level the ICD can reach.  
 
 
Fig. 11. Example of lead noise oversensing algorithm: Top line, near field EGM between tip 
to ring. Middle line, far field EGM between can to RV coil. Bottom line: marker channel. As 
the detection of noise continues, the algorithm withholds detection. Timeout is available to 
ensure that detection is not withheld for long periods of time. 
3.2.3 Shock reduction strategies 
Several recent publication have consistently demonstrated the usefulness of antitachycardia 
pacing and shock withholding for supraventricular rhythms, oversensing, and nonsustained 
ventricular tachycardia. During the following pages we will further discuss the evidence 
supporting this approach, as well as new developments incorporated in the newest devices 
to ensure correct VT diagnosis and delivery of shock only when needed. 
3.2.3.1 Antitachycardia pacing 
This function allows terminating VTs by pacing faster than the ventricular rate, thus 
blocking the re-entrant circuit sustaining the tachycardia. ATP is painless and much less 
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associated with atrial tachycardia induction. Nevertheless, it may accelerate the VT or even 
transform it into VF. 
There are several different types of ATP, basically referred to as burst and ramps. Burst 
means that all the stimulation pulses given during the ATP maintain the same interval 
whereas ramp means that the pacing interval decreases from one beat to the following one 
(Figure 12). 
 
 
 
 
Fig. 12. Top. Burst pacing: after VT is detected, burst pacing is initiated. 2 sequences of 6 
beats each are programmed, with a 91% coupling interval and 10 ms decrement between 
both. Bottom. Ramp pacing: only 2 sequences programmed, first one 4 beats, second one of 
5. During ramp pacing, the 10 ms decrement programmed decreases each pacing interval in 
the same sequence. 
Burst 
Ramp 
www.intechopen.com
 New Ways to Avoid Unnecessary and Inappropriate Shocks 
 
95 
ATP effectiveness is related to tachycardia cycle length, being higher in slower VTs and 
decreasing for VTs faster than 200 bpm (Ormaetxe-Merodio et al, 2008).  Several 
publications have compared effectiveness and safety of both types of ATP, without finding 
statistically significant differences for slow VTs. Nevertheless, the PITAGORA ICD trial 
(Gulizia et al, 2009) randomized patients to one burst (eight stimuli, 88% of the cycle length) 
versus one ramp (eight stimuli, 91% cycle length) in the FVT zone (188–250 bpm). Bursts had 
a significantly higher success rate than ramps (72% vs 52%) for fast VTs, with a trend toward 
less acceleration (2.3% vs 7.4%).  
There are some ICD models that memorize therapy effectiveness but it is known that failure 
of an ATP sequence does not predict subsequent failure. For Medtronic devices, in case it 
does not appear in four consecutive episodes, the device annulates it and, for the next 
episode, jumps directly to the next therapy programmed (Smart mode). Biotronik has a 
programmable option: ATP optimization. A successful ATP setting is memorized by the 
ICD and delivered as the first therapy for future events. 
Concerning the number of pulses to use and stimulation rate, published data is scarce. 
Peinado et al, 1998, compared the efficacy and safety of different ATPs, namely 15 vs 7 
pulses at rates of 91 vs 81% of tachycardia cycle length. They showed that for an isolated 
sequence of stimulation, burst pacing using 15 pulses was more effective than 7 pulses (78% 
vs 68%, p: 0,01) and stimulation rates of 91% of the tachycardia cycle length were better than 
81% (80% vs 56%, p<0,001). So the authors conclude than ATP using 15 pulses at 91% of 
tachycardia cycle length was the most effective combination (87%, p<0,001 in comparison 
with the other ATP combinations). 
Due to the scarce data we have concerning number of pulses to program, is our usual policy 
to program 10-12 pulses at 88-91% of tachycardia cycle length. 
We can say that ATP in ICD recipients allows to successfully terminate 85-90% of VTs with 
cycle length higher than 320 ms, with a low acceleration rate (1-5%). Besides, these figures 
are applicable to different cardiomyopathies (ischemic and non-ischemic), confirming 
reentry as the most probable mechanism of these arrhythmias. 10 to 25% of ICD recipients 
present VTs with a CL lower than 320 ms. Even though effectiveness is lower than for 
slower VTs, there are published data supporting their use. In this way, Wathen et al 2001 
(Pain-FREE trial), analyzed ATP results when using 2 burst of 8 pulses at 88% of tachycardia 
CL for VTs between 240 and 320 ms. Out of 442 studied episodes in 52 ischemic patients, 
85% successfully terminated with the therapy, 90% with the first delivered burst. On top of 
that, a third therapy programmed in some patients by caring physician criteria successfully 
terminated 18 more VTs, rising global efficacy to 89%. With this stimulation protocol, VT 
acceleration rate was only 4%.  
Several years later, Wathen et al published the Pain-FREE II trial (Wathen et al, 2004), 
comparing only one burst of 8 pulses at 88% with high energy shocks for VTs between 188 
and 250 bpm. 1837 episodes were able for analysis, 73% of witch corresponded to 
monomorphic fast VTs. ATP efficacy for VTs faster than 188 bpm was 81%, with an 
acceleration rate of only 2%. On the population randomized to receive shocks, 34% of 
episodes ended spontaneously and 66% required the programmed therapy. So, shock 
reduction by using ATP for fast VTs was 70% in this study. Mean duration of episodes was 
shorter in the ATP group (10,7±0,7  vs 12,7±0,8 ms; p<0,001). There were no differences 
between groups in sincopal episodes. Another important finding in this study was the fact 
that the number of intervals to detect the tachycardia was prolonged to 18, compared to 12 
for the Pain-FREE I. That reduced significantly the number of episodes that required 
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therapy, and settled the fundamentals for more recent studies investigating the results of 
prolonging the time to detect the tachyarrhythmia and start treatment. 
Several smaller but more recent studies have also demonstrated that ATP is safe and 
effective for fast VTs termination. Following this evidence, most of the newest devices from 
different manufacturers offer the possibility of antitachycardia pacing delivery during ICD 
charging. The obvious advantage of ATP during charging is that, in case the VT terminates, 
the shock is avoided and, in case it does not, successful therapy is not delayed. One step 
forward is to deliver ATP even before initiating ICD charging. In case of success, not only 
shocks are avoided, but also battery depletion due to repeated charging thus prolonging 
ICD total life. 
A less studied issue is the number of ATP attempts (burst or ramps) that are to be 
programmed. Published evidence shows that the majority of VTs ended with the first 
ATP, but is far from negligible the episodes terminated by the second or even the third 
attempt, not only for slow VTs but also for the fast ones. The main advantage of several 
ATPs programmed is avoiding shock delivery to terminate the episode. On the contrary, 
the risk is to prolong VT total duration, that could be dangerous depending on 
arrhythmia tolerance. So we have to tailor the therapy by programming different 
VT/FVT/VF zones and therapies on each, guided by cycle length and arrhythmia 
tolerability in each patient.  
The PainFREE RX II (Pacing Fast VT REduces Shock ThErapies) and EMPIRIC 
(Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter 
Defibrillators) trials demonstrated that specific VT and VF detection and therapy 
programming strategies reduced the frequency of shocked episodes. The use of detection 
algorithms designed to distinguish supraventricular and ventricular tachyarrhythmias 
and the use of ATP to terminate rapid VTs have been reported to be important 
components of programming strategies designed to optimize ICD programming and to 
reduce unnecessary shocks. Sweeny et al recently published that, combining the data of 
the studies PainFREE I & II, EMPIRIC and PREPARE, most ventricular episodes were 
potentially ATP-terminable VTs or FVTs, since ATP was able to terminate 92,4% of VT 
and 82,5% of FVT episodes attempted. 
On the basis of this data, we think that programming the VT zone should include at least 
four ATPs, and for fast VTs, the weight of evidence suggests that at least one ATP sequence 
should be programmed for VTs between 188 and 250 bpm and that two sequences are 
superior to one. 
3.2.3.2 Shock withholding for supraventricular rhythms, oversensing, and nonsustained 
ventricular tachycardia 
The PREPARE (Programming of Detection and Therapy Parameters in ICDs Reduces 
Shock) trial was a prospective, cohort-controlled study that analyzed 700 patients with 
primary prevention indications for an ICD followed for 1 year. VT/VF was detected for 
rates ≥182 beats/min that were maintained for at least 30 of 40 beats. ATP was 
programmed as the first therapy for regular rhythms with rates of 182 to 250 bpm, and 
SVT discriminators were used for rhythms ≤200 bpm. The primary end point was a 
combined morbidity index, including incidence of device-delivered shocks, arrhythmic 
syncope, and untreated sustained symptomatic VT/VF. The authors demonstrated that 
programming strategies that prolong detection duration (30 of 40 ventricular beats), 
increase the heart rate threshold of tachycardia detection (182 beats/min), use 
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supraventricular detection discrimination algorithms and ATP, and encourage first shock 
termination of tachyarrhythmias can safely and substantially reduce the number of 
tachyarrhythmias subjected to shock therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13. Data from the PREPARE study. Both appropriate and inappropriate shocks were 
substantially reduced in the PREPARE study programmed patients. (Reproduced from 
Wilkoff et al, 2008). 
The PREPARE study data clearly demonstrate that by waiting and permitting nonsustained 
and slower arrhythmias to self-terminate, there are fewer shocked and treated ventricular 
and SVTs. 
New ways of further advancing our knowledge about how to avoid inappropriate and 
unnecessary shocks have been recently published (Volosin et al, 2011). The authors 
developed and validated a computer model using clinical data from other published ICD 
studies and nicely demonstrated how, by using the shock reduction strategies tested (see 
table 1), hypothetically were able to reduce the number of VT/VF shocked episodes in the 
SCD-HeFT ICD population by an estimated 59% (from 952 observed to 395 modelled 
shocks, probability of >0.999). The percentage of patients experiencing inappropriate shocks 
over 5 years was decreased by 15% (23.5–8.4%), and the number of shocks for non-VT/VF 
episodes was decreased from 423 to 77 (82% reduction). 
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Reducing Inappropriate Shocks 
1. Using SVT discriminators to cycle lengths of 260 ms or greater. 
2. Longer detection time to allow more episodes to terminate spontaneously. 
3. Enhanced T wave oversensing algorithm avoids shocks due to oversensed T 
waves. 
4. Lead noise algorithm avoids shocks due to noise oversensing. 
5. Combination of atrial and ventricular timing/pattern analysis (PR Logic) 
with electrogram morphology analysis (Wavelet). 
6. Tachycardia detection rate cutoff. 
Reducing Unnecessary Shocks 
1. ATP therapies to a cycle length of 240 ms. 
2. Longer detection time to allow more episodes to terminate spontaneously. 
3. New synchronization intervals to reduce shocks for nonsustained events. 
4. Tachycardia detection rate cutoff. 
Table 1. Strategies for reducing ICD Shocks tested by Volosin et al, 2011. 
4. Conclusions 
The number of unnecessary or inappropriate shocks is still not zero, which is the goal. ICD 
discharges have a negative impact on patient prognosis and quality of life, so every effort 
should be made by programming physicians and ICD manufacturers to reach this goal. 
It has been suggested that the “out of box” settings for current ICD systems should be 
changed in light of the programming strategies shown in clinical trials to reduce shocks, and 
some manufacturers are already working on it. This may be worthwhile but, since there are 
so many patient specific issues to be considered, the important point is that the devices 
should be optimally programmed at implant, not how the devices are shipped.  
The initial one-zone one-lead “shock box” approach has progressively become obsolete, as 
attention has increasingly turned toward avoidance of preventable shocks and 
inappropriate therapies for lead failure, SVT, and self-terminating tachyarrhythmias. ATP 
therapy should be systematically programmed, algorithms to discriminate from 
supraventricular rhythms are to be used and spontaneous episodes of VT have to be 
aggressively treated, with special consideration to ablation.  Recently published evidence 
suggests that shock reduction strategies could and should be combined to reduce the 
incidence of unnecessary and inappropriate ICD shocks. New discrimination algorithms 
could significantly increase specificity without affecting sensitivity.  
As in many other fields in Medicine and to the greatest extent possible, ICD programming 
should be guided by evidence based medicine and every effort should be made to translate 
this evidence to bedside by ICD programming physicians. 
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